Published online before print May 25, 2006, doi: 10.1161/01.ATV.0000228824.01604.63
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 American Heart Association, Inc.
Vascular Biology |
Increased Expression of Elastolytic Cathepsins S, K, and V and Their Inhibitor Cystatin C in Stenotic Aortic Valves
From the Wihuri Research Institute (S.H., S.S., K.A.L., J.L., K.O., M.I.M., P.T.K.), Helsinki, Finland; and Division of Cardiology, Department of Medicine (J.L., H.T., M.K.) and Division of Cardiothoracic Surgery, Department of Surgery (K.W.), Helsinki University Central Hospital, Helsinki, Finland.
Correspondence to Petri Kovanen, Wihuri Research Institute, Kalliolinnantie 4, FIN-00140 Helsinki, Finland. E-mail petri.kovanen{at}wri.fi
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Objective— To investigate the possible role of elastolytic cathepsins S, K, and V and their endogenous inhibitor cystatin C in adverse extracellular matrix remodeling of stenotic aortic valves.
Methods and Results— Stenotic aortic valves were collected at valve replacement surgery and control valves at cardiac transplantations. The expression of cathepsins S, K, and V and cystatin C was studied by conventional and real-time polymerase chain reaction and by immunohistochemistry. Total cathepsin activity in the aortic valves was quantified by a fluorometric microassay. When compared with control valves, stenotic valves showed increased mRNA expression of cathepsins S, K, and V (P<0.05 for each) and a higher total cathepsin activity (P<0.001). In stenotic valves, cystatin C mRNA was increased (P<0.05), and cystatin C protein was found particularly in areas with infiltrates of inflammatory cells. Both cathepsin S and cystatin C were present in bony areas of the valves, whereas cathepsin V localized to endothelial cells in areas rich of neovascularization. Incubation of thin sections of aortic valves with cathepsins S, K, and V resulted in severe disruption of elastin fibers, and this cathepsin effect could be blocked by adding cystatin C to the incubation system.
Conclusions— Stenotic aortic valves show increased expression and activity of elastolytic cathepsins S, K, and V. These cathepsins may accelerate the destruction of aortic valvular extracellular matrix, so promoting the progression of aortic stenosis.
Here, we demonstrate increased expression and activity of the elastolytic cathepsins S, K, and V and their endogenous inhibitor cystatin C in stenotic aortic valves. These findings suggest that these cathepsins may participate in the adverse remodeling of the valves and accelerate the progression of aortic stenosis.
Key Words: aortic stenosis • cathepsin • cystatin C • elastin • heart valves
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Aortic stenosis is an active inflammatory process resembling atherosclerosis. The pathophysiological changes in the stenotic aortic valves include inflammatory cell infiltration, neoangiogenesis, accumulation of lipids, and active mediators of calcification with extracellular matrix (ECM) degradation.1–7 Furthermore, aortic valvular myofibroblasts undergo phenotypic changes toward an osteoblast-like phenotype, and active bone formation and remodeling occur in the stenotic valves.8,9 These processes lead to loss of normal valvular geometry, disruption of the elastic fibers, and accumulation of fibrocalcific masses. This adverse remodeling of the valves is associated with the loss of their mechanical and elastic properties, leading to thickening and stiffening of the valve leaflets and to progression of aortic stenosis.
The pathophysiological mechanisms involved in the abnormal accumulation and degradation of ECM in the valves are incompletely understood. In atherosclerotic lesions, elastolytic cysteine proteases, including cathepsins S and K, are overexpressed at sites of arterial elastin damage, whereas their endogenous inhibitor, cystatin C, is severely reduced.10,11 Moreover, a marked deficiency of cystatin C expression with accentuated cathepsin S and K expression in aortic aneurysms and a negative correlation of cystatin C serum levels with the diameter of abdominal aorta has been reported.11 These observations support the role of an imbalance between cathepsins and cystatin C in diseases characterized by pathological elastin degradation. In addition, cathepsin K has a crucial role in bone matrix degradation necessary for normal bone growth and remodeling,12 whereas cystatin C inhibits both bone resorption and osteoclast formation.13 In cathepsin K–deficient mice, impaired bone resorption leads to an osteopetrotic-like phenotype, and patients with single-point mutations in the cathepsin K gene, resulting in a lack of cathepsin K activity, develop severe osteopetrosis.14–16 Because cathepsin S was shown recently to participate in ECM degradation during microvessel formation,17 this cathepsin and perhaps also other cathepsins may participate in neoangiogenesis, a process critical for progression of aortic stenosis.7,18
The possible role of cathepsins and cystatin C in the pathogenesis of aortic stenosis has not been examined previously. Moreover, there are no data available on the possible role of the elastolytic protease cathepsin V in cardiovascular diseases. The aim of our study was to determine whether the elastolytic cathepsins S, K, and V and their inhibitor cystatin C are present at stenotic aortic valves and whether they might participate in the ECM remodeling known to associate with the progression of aortic stenosis.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
For Methods, please see the online supplement, available at http://atvb.ahajournals.org.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Levels of mRNA Expression in Control and Stenotic Valves
RT-PCR revealed that cathepsins S and K and cystatin C were produced locally in both stenotic and control aortic valves. The mRNA expression levels of cathepsin S and cathepsin K were significantly higher in the stenotic than in the control valves (median [range] 2.3 [0.4 to 14.6] versus 1.4 [0.3 to 6.5] arbitrary units [AU]; P<0.05; and 2.9 [1.2 to 21.3] versus 1.9 [0.9 to 5.7] AU; P<0.05, Figure 1A). Similarly, we observed a significant increase in the mRNA expression level of cystatin C (3.6 [1.1 to 18.0] versus 2.2 [1.1 to 9.5] AU; P<0.05; Figure 1A) in the stenotic aortic valves compared with control valves. Using real-time PCR, cathepsin V was also found to be produced locally in all studied aortic valves, and similar to cathepsins S and K, the mRNA expression levels of cathepsin V were significantly higher in the stenotic valves than in the control valves (4.5 [0.4 to 79.1] versus 0.9 [0.03 to 14.5] AU; P<0.01; Figure 1B). A positive correlation appeared between the mRNA expression levels of cathepsin S and K (r=0.86; P<0.001) as well as between the mRNA levels of cathepsin S and V (r=0.86; P<0.001), and cathepsins K and V (r=0.81; P<0.001). Moreover, the mRNA expression levels of all 3 cathepsins correlated positively with those of cystatin C (r=0.91 for cathepsin S, r=0.87 for cathepsin K, and r=0.86 for cathepsin V; P<0.001 for all). The mRNA expression levels were similar in both tricuspid and bicuspid stenotic aortic valves. In addition, patients with aortic stenosis who received statin treatment (n=9) had a tendency toward lower mRNA expression levels of cathepsins S and K and also of cystatin C (data not shown).
|
Immunohistochemical Detection of Cathepsin S, Cathepsin V, and Cystatin C
Immunohistochemistry showed that cathepsin S was more abundant in the stenotic than in the control aortic valves (Figure 2A and 2B). In the stenotic valves, positive staining of cathepsin S was found in superficial endothelium lining the valves and also in the deeper areas rich of inflammatory cells. In contrast, in the control aortic valves, cathepsin S protein was detected only in the superficial endothelium lining the valves. Double immunofluorescence stainings demonstrated that cathepsin S colocalized with macrophages in the inflammatory areas of the stenotic valves (Figure 2C through 2E), and large regional differences in the amount of cathepsin S–positive macrophages between the different valvular regions were observed. In addition, cathepsin S protein was detected in the ossified areas of the valves, where it appeared as a perinuclear rim in the majority of the S100-positive chondroblast-like cells, suggesting active cathepsin S synthesis by these cells (Figure 2F through 2H). Colocalization of cathepsin S and cystatin C was detected in the superficial endothelium lining the valves as well as in a fraction of macrophages in the stenotic valves (Figure 2I through 2K).
|
Cathepsin V was present in the endothelium lining the valve leaflets of both stenotic and control valves (Figure 3A and 3B). Importantly, in stenotic aortic valves, strong cathepsin V staining was also detected in the endothelial cells forming the neovessels within the valves (Figure 3C and 3D). Double immunofluorescence stainings (Figure 3E through 3J) confirmed colocalization of cathepsin V and endothelial cells, both in thick-walled (Figure 3E through 3G) and thin-walled (Figure 3H through 3J) neovessels. In the thick-walled vessels, some cathepsin V staining was also observed in the surrounding pericytes (Figure 2F).
|
Cystatin C protein was detected both in the stenotic and in the control valves. However, the staining intensity of cystatin C appeared stronger in the stenotic than in the control aortic valves. In control valves, most of the cystatin C staining was present in acellular areas (Figure 4A), whereas in stenotic valves, cystatin C was typically present both intracellularly and extracellularly in cell-rich areas (Figure 4B). Similar to cathepsin S, cystatin C was also found in the majority of the chondroblast-like cells in bony areas of the stenotic valves (Figure 4C and 4D). As shown in Figure 5, strong cystatin C staining was detected in areas rich of inflammatory cells, notably macrophages (Figure 5A and 5B). Moreover, in stenotic leaflets, cystatin C protein was found in the areas where elastin fibers were preserved (Figure 5B and 5C). Double immunofluoresence stainings revealed the colocalization of cystatin C and macrophages, with approximately one third of the macrophages showing positive signals. (Figure 5D through 5I). As shown in Figure 5J through 5L, cystatin C was detected in the superficial endothelium lining the valve leaflets. In contrast, cystatin C was absent from the endothelial cells forming the neovessels of the stenotic aortic valves (Figure 5M through 5O). Negative controls of all immunohistochemical and double immunofluorescence stainings are shown in supplemental Figures I and II (available online at http://atvb.ahajournals.org).
|
|
Degradation of the Aortic Valvular Elastin Fibers by Cathepsins S, K, and V Ex Vivo
Histological staining of elastin and collagen fibers revealed a pattern of degradation and disorientation of elastin fibers in the stenotic aortic valves, whereas the majority of the elastin fibers in the control aortic valves were intact. The observed in vivo pattern of elastin degradation could be mimicked in vitro by incubating cryostat sections of control aortic valves with recombinant human cathepsin S, K, and V. Figure 6A demonstrates the quantitative results of the analysis of valvular elastin fibers by computer-assisted morphometry. The average content of elastin fibers in the control aortic valves was 45±17% before incubation and 45±16% after incubation (24-hour) of the sections with a control buffer and 56±3% after incubation with recombinant cystatin C. Incubating frozen tissue sections of control aortic valves with cathepsin S decreased the valvular elastin content to 25±12% (P<0.01). Similarly, incubating sections with cathepsin K and cathepsin V decreased the valvular elastin content to 33±13% (P<0.01) and 34±13% (P<0.01), respectively. The elastin degradation effects of all cathepsins tested were inhibited by exogenous cystatin C (Figure 6A). Histological stainings of the sections demonstrating degradation of the elastin fibers (dark purple) by the studied cathepsins are shown in supplemental Figure III.
|
Determination of Cathepsin Activity in the Aortic Valves
Direct determination of total cathepsin activity in tissue sections using a fluorometric microassay showed the presence of enzymatically active cathepsins in both control and stenotic aortic valves. However, in stenotic aortic valves, the level of enzymatically active cathepsins was significantly higher than in the control valves (P<0.001; Figure 6B). The level of total cathepsin activity in the tissue sections from the stenotic valves equaled the activity of 20 nmol/L recombinant human cathepsin V and was 3.4-fold higher than the activity of 20 nmol/L recombinant cathepsin S. Degradation of the cathepsin-specific substrate Z-Phe-Arg-AMC, reflecting cathepsin activity, could be completely inhibited by adding the cathepsin inhibitor E-64 to the incubation system (Figure 6B).
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
This is the first study to suggest a potential involvement of cathepsins S, K, and V in the pathogenesis of aortic stenosis. The increased levels of these elastolytic cathepsins in stenotic aortic valves and their ability to degrade aortic valvular elastin suggest that they may disturb the balance between matrix synthesis and degradation in the diseased valves. Such disequilibrium between the synthesis and degradation of ECM components, notably collagen and elastin, would then lead to pathological remodeling and stiffening of the valve leaflets. The degree of cathepsin-mediated matrix degradation is regulated by their natural inhibitor, cystatin C, and, accordingly, we found that its expression was increased in the stenotic aortic valves. The factors, which stimulate cystatin C expression in the stenotic valves, are unknown. However, cystatin C secretion is induced by transforming growth factor-ß1, which is abundantly expressed in stenotic valves,11,19 so rendering it possible that transforming growth factor-ß1 acts as a stimulator of cystatin C expression in the valves. The present observation that an upregulation of cathepsins in stenotic valves is accompanied by an elevated level of cystatin C differs from that of atherosclerotic lesions, in which increased cathepsin activity has been found to associate with decreased cystatin C expression.11 Whether the increased amounts of cystatin C in stenotic aortic valves are sufficient to inhibit the elevated levels of elastolytic cathepsins in the valves is presently unknown. Our observation that tissue sections of the stenotic aortic valves contained active cathepsins would suggest that the increased expression of cystatin C is not sufficient to fully inhibit the increased cathepsin activity. Also, the differential localization of cathepsins and cystatin C in the diseased aortic valves reveals that local areas expressing active cathepsins but lacking cystatin C exist and so provide potential explanation for the observed destruction of the valvular elastin fibers despite upregulation of cystatin C. Importantly, by measuring mRNA expression, we observed local production of the 3 cathepsins and cystatin C in the aortic valves. Moreover, immunostainings showed cathepsin-positive endothelial cells, macrophages, and chondroblast-like cells in the stenotic valves, suggesting local secretion of the studied cathepsins. However, we cannot rule out the possibility that a fraction of these molecules have entered the valve leaflets from the circulation.
In addition to the cathepsins, matrix metalloproteinases (MMPs) may contribute to the degradation of ECM components in aortic valves. Indeed, an increased expression and activity of MMPs in stenotic aortic valves have been demonstrated.20–22 Locally produced cytokines, such as tumor necrosis factor-
, may stimulate the expression and activation of MMPs in stenotic valves22 and induce secretion of cathepsin S by endothelial cells and smooth muscle cells.10,17 Thus, an increased production of proinflammatory cytokines by infiltrating inflammatory cells may be responsible for the local upregulation of both cathepsins and MMPs in stenotic aortic valves. However, increased expression of MMPs in the stenotic valves is also accompanied by overexpression of their natural inhibitors, the tissue inhibitors of MMPs.21 Actually, Fondard et al reported that the tissue inhibitor of MMP-1/MMP-9 ratio was significantly increased in stenotic aortic valves.21 Therefore, alternative pathways of matrix degradation independent of MMPs are likely to contribute to the adverse remodeling of the valves. In the present work, frozen aortic valves were incubated with recombinant cathepsins in the presence of EDTA, which, by chelating divalent cations, efficiently blocks MMP activity, and therefore, the elastin degradation presented in Figure 6A has occurred largely without the action of MMPs.
Cathepsin V, a novel member of the cysteine protease family, possesses by far the most potent elastase activity described.23 Although the presence of cathepsin V protein in atheroma tissue has been suggested,23 its role in the pathogenesis of cardiovascular diseases is unknown. Cathepsin V is closely related to cathepsin L, which is expressed abundantly in aortic aneurysms and atherosclerotic tissue, and the serum levels of which are elevated in patients with coronary artery stenosis.24 Previous reports of the strong elastolytic activity of cathepsin V23 and our present findings of increased cathepsin V mRNA expression in stenotic aortic valves suggest a role for this enzyme in the degradation of valvular elastin. The strong immunoreactivity of cathepsin V in the endothelial cells lining the neovessels of the stenotic valves renders it possible that this cathepsin, like cathepsin S, may promote invasion of endothelial cells and neovessel growth.17 Indeed, neovascularization of the normally avascular valve tissue is a prominent feature of aortic stenosis.7,18 Interestingly, in the stenotic valves, the cells surrounding the neovessels were cystatin C positive, but the neovessels themselves were cystatin C negative (Figure 5M through 5O). These findings suggest that cathepsins and cystatin C may regulate the growth of microvessels during the progression of aortic stenosis and that a local imbalance of elastolytic cathepsins and their inhibitor cystatin C may have promoted neovessel formation in the stenotic aortic valves. Because microvessel formation is likely to facilitate recruitment of inflammatory cells and accumulation of plasma lipids into the aortic valve leaflets, it may also, via these actions, promote fibrocalcific thickening of the valves. Accordingly, local inhibition of cathepsins could reduce valvular neoangiogenesis and retard aortic stenosis progression.
Active bone formation, expression of osteogenic factors, and conversion of valvular myofibroblasts into an osteoblastic phenotype with the development of calcific nodules are typical features of aortic stenosis.8,9,25 Indeed, calcification is a major determinant of leaflet stiffness in severe aortic stenosis,26 and it is associated with rapid hemodynamic progression of the disease.27 Dystrofic calcification and even endochondral bone formation and bone remodeling occur in the stenotic aortic valves.8 In the present study, cathepsin K, the major protease involved in bone matrix remodeling,12 was highly upregulated in the calcified stenotic valves when compared with the control valves. In addition, both cathepsin S and cystatin C protein were present in the chondroblast-type cells in the samples of stenotic valves that contained bone tissue. The present findings suggest that similar to their roles in the skeleton, cathepsins and cystatin C may also regulate calcification and bone formation in aortic valves. Indeed, cystatin C is present both in preosteoblasts and mature osteoblasts28 and is able to prevent the osteoclastic degradation of bone matrix proteins induced by cathepsin K.13 Thus, in stenotic aortic valves, cathepsins could degrade matrix at sites of bone formation, so reducing ossification of the valves, whereas cystatin C could accelerate bone formation by inhibiting these processes in the valves. Currently, in atherosclerotic plaques and aortic aneurysms, the role of elastolytic cathepsins is considered to be adverse because they likely promote plaque weakening and dilatation of the aortic aneurysms, whereas their inhibitor cystatin C is considered to be a protective factor. However, in the pathogenesis of aortic stenosis, this simple dichotomy may not apply, and dual roles of both cathepsins and cystatin C merit consideration (ie, elastin degradation and neovascularization being harmful, and resorption of the ossified structures of the end-stage stenotic valves representing a mechanism ultimately limiting the disease progression). Finally, in statin-treated patients, there was a tendency toward lower expression levels of cathepsins S and K, and also of cystatin C, a finding that may partly explain the previous observation of statin treatment being able to inhibit calcification of the aortic valves.29
In summary, here, we report an association of cathepsins S, K, and V and their inhibitor cystatin C with calcific aortic valve disease and suggest that these enzymes may participate in the adverse ECM remodeling of stenotic aortic valves. In addition, intense association of cathepsin V with neovessels of the stenotic aortic valves suggests a role for this enzyme in the neovascularization of the valves. Because both cathepsin S and cystatin C were detected in chondroblast-like cells of the valves, these molecules may also participate in bone formation and remodeling observed in the stenotic valves. These findings urge for a more precise definition of the role of the cathepsins and cystatin C in the pathophysiology of aortic stenosis. If clinically significant, elastolytic cathepsins may represent novel therapeutic targets in the so far unsuccessful pharmacological prevention of aortic stenosis.30
Study Limitations
Because normal, fresh surgical samples of aortic valves are rarely available, the control group consisted of both organ donors without cardiovascular diseases and patients undergoing cardiac transplantation. However, only macroscopically and microscopically normal valves were accepted in the control group, and no statistically significant differences in any of the investigated parameters were observed between these 2 control subgroups.
|
Acknowledgments |
|---|
We sincerely thank Dr Dieter Brömme for having provided us with the cathepsin K enzyme. We thank Mia Sneck for her kind help in establishing the method for fluorometric quantification of the cathepsin activity. We also acknowledge Liisa Blubaum, Elina Kaperi, Anna Oksaharju, and Suvi Mäkinen for excellent technical assistance.
Sources of Funding
This work was supported by the Finnish Foundation for Cardiovascular Research, Helsinki, Finland (S.H.), the Sigrid Juselius Foundation, Helsinki, Finland, the EVO research funds of Helsinki University Central Hospital, and the Academy of Finland (K.Ö.).
Disclosures
Wihuri Research Institute is maintained by the Jenny and Antti Wihuri Foundation.
|
Footnotes |
|---|
Original received December 29, 2005; final version accepted May 8, 2006.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O’Brien KD. Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis. Histological and immunohistochemical studies. Circulation.. 1994; 90: 844–853.
2. Olsson M, Dalsgaard CJ, Haegerstrand A, Rosenqvist M, Ryden L, Nilsson J. Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J Am Coll Cardiol. 1994; 23: 1162–1170.[Abstract]
3. Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol. 1999; 19: 1218–1222.
4. Helske S, Lindstedt KA, Laine M, Mayranpaa M, Werkkala K, Lommi J, Turto H, Kupari M, Kovanen PT. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol.. 2004 2; 44: 1859–1866.
5. O’Brien KD, Kuusisto J, Reichenbach DD, Ferguson M, Giachelli C, Alpers CE, Otto CM. Osteopontin is expressed in human aortic valvular lesions. Circulation.. 1995 15; 92: 2163–2168.
6. O’Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of ‘degenerative’ valvular aortic stenosis. Arterioscler Thromb Vasc Biol. 1996; 16: 523–532.
7. Soini Y, Salo T, Satta J. Angiogenesis is involved in the pathogenesis of nonrheumatic aortic valve stenosis. Hum Pathol. 2003; 34: 756–763.[CrossRef][Medline] [Order article via Infotrieve]
8. Mohler ER III, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. Circulation.. 2001 20; 103: 1522–1528.
9. Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M, Orszulak T, Fullerton DA, Tajik AJ, Bonow RO, Spelsberg T. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation.. 2003 6; 107: 2181–2184.
10. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest.. 1998 1; 102: 576–583.[Medline] [Order article via Infotrieve]
11. Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, Ridker PM, Libby P, Chapman HA. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest. 1999; 104: 1191–1197.[Medline] [Order article via Infotrieve]
12. Bossard MJ, Tomaszek TA, Thompson SK, Amegadzie BY, Hanning CR, Jones C, Kurdyla JT, McNulty DE, Drake FH, Gowen M, Levy MA. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J Biol Chem.. 1996 24; 271: 12517–12524.
13. Brage M, Abrahamson M, Lindstrom V, Grubb A, Lerner UH. Different cysteine proteinases involved in bone resorption and osteoclast formation. Calcif Tissue Int. 2005 76: 439–447.
14. Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, Moritz JD, Schu P, von FK. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A.. 1998 10; 95: 13453–13458.
15. Gowen M, Lazner F, Dodds R, Kapadia R, Feild J, Tavaria M, Bertoncello I, Drake F, Zavarselk S, Tellis I, Hertzog P, Debouck C, Kola I. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res. 1999; 14: 1654–1663.[CrossRef][Medline] [Order article via Infotrieve]
16. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 1996; 273: 1236–1238.[Abstract]
17. Shi GP, Sukhova GK, Kuzuya M, Ye Q, Du J, Zhang Y, Pan JH, Lu ML, Cheng XW, Iguchi A, Perrey S, Lee AM, Chapman HA, Libby P. Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ Res. 2003; 92: 493–500.
18. Mazzone A, Epistolato MC, De Caterina R, Storti S, Vittorini S, Sbrana S, Gianetti J, Bevilacqua S, Glauber M, Biagini A, Tanganelli P. Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis. J Am Coll Cardiol.. 2004 5; 43: 1670–1676.
19. Jian B, Narula N, Li QY, Mohler ER III, Levy RJ. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg. 2003; 75: 457–465.
20. Satta J, Oiva J, Salo T, Eriksen H, Ohtonen P, Biancari F, Juvonen TS, Soini Y. Evidence for an altered balance between matrix metalloproteinase-9 and its inhibitors in calcific aortic stenosis. Ann Thorac Surg. 2003; 76: 681–688.
21. Fondard O, Detaint D, Iung B, Choqueux C, dle-Biassette H, Jarraya M, Hvass U, Couetil JP, Henin D, Michel JB, Vahanian A, Jacob MP. Extracellular matrix remodeling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur Heart J. 2005; 26: 1333–1341.
22. Kaden JJ, Dempfle CE, Grobholz R, Fischer CS, Vocke DC, Kilic R, Sarikoc A, Pinol R, Hagl S, Lang S, Brueckmann M, Borggrefe M. Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol. 2005; 14: 80–87.[CrossRef][Medline] [Order article via Infotrieve]
23. Yasuda Y, Li Z, Greenbaum D, Bogyo M, Weber E, Bromme D. Cathepsin V, a novel and potent elastolytic activity expressed in activated macrophages. J Biol Chem.. 2004 27; 279: 36761–36770.
24. Liu J, Sukhova GK, Yang JT, Sun J, Ma L, Ren A, Xu WH, Fu H, Dolganov GM, Hu C, Libby P, Shi GP. Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. Atherosclerosis. 2006 184: 302–311.[CrossRef][Medline] [Order article via Infotrieve]
25. Mohler ER III, Chawla MK, Chang AW, Vyavahare N, Levy RJ, Graham L, Gannon FH. Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis. 1999; 8: 254–260.[Medline] [Order article via Infotrieve]
26. Warren BA, Yong JL. Calcification of the aortic valve: its progression and grading. Pathology. 1997; 29: 360–368.[CrossRef][Medline] [Order article via Infotrieve]
27. Rosenhek R, Klaar U, Schemper M, Scholten C, Heger M, Gabriel H, Binder T, Maurer G, Baumgartner H. Mild and moderate aortic stenosis. Natural history and risk stratification by echocardiography. Eur Heart J.. 2004; 25: 199–205.
28. Raouf A, Seth A. Discovery of osteoblast-associated genes using cDNA microarrays. Bone. 2002; 30: 463–471.[Medline] [Order article via Infotrieve]
29. Rajamannan NM, Subramaniam M, Springett M, Sebo TC, Niekrasz M, McConnell JP, Singh RJ, Stone NJ, Bonow RO, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation.. 2002 4; 105: 2660–2665.
30. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med.. 2005 9; 352: 2389–2397.
This article has been cited by other articles:
 |
|
 |
|
  E. Aikawa, M. Aikawa, P. Libby, J.-L. Figueiredo, G. Rusanescu, Y. Iwamoto, D. Fukuda, R. H. Kohler, G.-P. Shi, F. A. Jaffer, et al. Arterial and Aortic Valve Calcification Abolished by Elastolytic Cathepsin S Deficiency in Chronic Renal Disease Circulation, April 7, 2009; 119(13): 1785 - 1794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Parolari, C. Loardi, L. Mussoni, L. Cavallotti, M. Camera, P. Biglioli, E. Tremoli, and F. Alamanni Nonrheumatic calcific aortic stenosis: an overview from basic science to pharmacological prevention Eur. J. Cardiothorac. Surg., March 1, 2009; 35(3): 493 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Balachandran, P. Sucosky, H. Jo, and A. P. Yoganathan Elevated cyclic stretch alters matrix remodeling in aortic valve cusps: implications for degenerative aortic valve disease Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H756 - H764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Rajamannan Calcific Aortic Stenosis: Lessons Learned From Experimental and Clinical Studies Arterioscler. Thromb. Vasc. Biol., February 1, 2009; 29(2): 162 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Novinec, R. N. Grass, W. J. Stark, V. Turk, A. Baici, and B. Lenarcic Interaction between Human Cathepsins K, L, and S and Elastins: MECHANISM OF ELASTINOLYSIS AND INHIBITION BY MACROMOLECULAR INHIBITORS J. Biol. Chem., March 16, 2007; 282(11): 7893 - 7902. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||